The goal is to help patients use GLP-1 therapy safely and effectively with medical supervision
doi: 10.1097/ALN.0000000000000320
Similar content being viewed by others Introduction Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder that is characterized by insulin resistance, hyperglycemia, and pancreatic -cell dysfunction
Beyond semaglutide tablets, several companies are developing small-molecule GLP-1 receptor agonists that do not require peptide delivery
Pancreatitis, or inflammation of the pancreas, is another worry
Increasing the number of intestinal endocrine L-cells According to the impairment of L-cells development in T2DM, a promising strategy for treating T2DM is to increase the number of L-cells in the intestine, thereby increasing the production of GLP-1